… treatment of advanced cancer cases. However, most of the chemotherapeutic drugs suffer
from poor … A phase I doseescalating study of DaunoXome, liposomal daunorubicin, in metas…

… this study were related to catheter-related problems, poor … treated with consecutive
ePIPAC and oxaliplatin or cisplatin… In 2008 the first multicenter open label dose-escalating …

… to poor outcomes, including large tumor size, high tumor stage, … and/or ATRA combined
with oxaliplatin and 5-fluorouracil/… lipophilic natures) also limit their pharmacological use [132]. …

… Because of the huge plethora of target genes and our poor understanding of this … cancer
therapy based on pharmacological modulation of autophagy and to promote increased cancer …

… pathways in order to develop pharmacological inhibitors. As a … , poor prognosis and overall
survival (OS) in patients with … continuous monitoring of the liver function. Other adverse …

… regimen (5-FU, leucovorin, oxaliplatin, and irinotecan) or combination gemcitabine plus nab-…
In addition, novel promising targets for pharmacologic inhibition, such as heat shock protein …

… Liposomes modified with cRGD could deliver anti-cancer drugs such as paclitaxel, oxaliplatin,
… 2B3-101 is further tested in an Open-label, Phase I/IIa, dose-escalating study in patients …

… Several dietary and pharmacological interventions have … BCAT2 and BCKDHA knockdown
impaired pancreatic cancer … with chemotherapy (capecitabine plus oxaliplatin) [254]. PEG-…

… 5 years in cancer treatment by FDA are enlisted in Table 21.3. … hepatic metastases patients.
This outcome is followed by further clinical trials of Marimastat only in patients with cancer of …

… cancer patients presents significant hurdles due to high recurrence rates, rapid progression,
dissemination, and poor … improvements in bladder cancer treatment. Several evidences …